A Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas

The purpose of this study is to identify the most safe and tolerable dose of the study drug, DYP688 that can be given to patients. Also to evaluate how well DYP688 might work in treating certain types of cancer including the metastatic uveal melanoma and other melanomas with GNAQ/11 mutations (or genetic changes to the gene GNAQ/11). Metastatic means the disease has spread from an initial or primary site to a different areas of the body. DYP688 is a study treatment that has not been approved by the FDA. This study is the first time the study drug is being tested in humans.

Are you Eligible? (Inclusion Criteria)

• Must be 18 years old or older
• Must have confirmed metastatic melanoma
• No history of bone marrow or organ transplant